Regeneron Pharmaceuticals
$735.20Change from previous close: +0.05%Absolute change: +$0.39
At a glance
- Revenue growth
- +0.99%
- 2025 vs 2024
- Net income growth
- +2.09%
- 2025 vs 2024
- Net margin
- 31.4%
- 2024: 31.1%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 40,559 | 37,759 | 33,080 | 29,215 | 25,435 |
| Current assets | 18,022 | 18,661 | 19,479 | 15,884 | 14,015 |
| Cash and equivalents | 3,118 | 2,488 | 2,730 | 3,106 | 2,886 |
| Short-term investments | 5,487 | 6,524 | 8,115 | 4,636 | 2,809 |
| Receivables | 5,741 | 6,212 | 5,667 | 5,329 | 6,037 |
| Inventory | 3,201 | 3,087 | 2,581 | 2,402 | 1,951 |
| Net property, plant and equipment | 5,366 | 4,817 | 4,224 | 3,834 | 3,482 |
| Other intangible assets | 1,257 | 1,149 | 1,039 | 916 | 6.7 |
| Long-term investments | 10,595 | 9,060 | 5,471 | 6,640 | 6,878 |
| Current liabilities | 4,368 | 3,944 | 3,423 | 3,141 | 3,933 |
| Accounts payable | 939 | 790 | 607 | 589 | 564 |
| Long-term debt | 1,986 | 1,984 | 1,983 | 1,981 | 1,980 |
| Total debt | 2,706 | 2,704 | 2,703 | 2,701 | — |
| Total liabilities | 9,302 | 8,406 | 7,107 | 6,551 | 6,666 |
| Total equity (incl. minority) | 31,257 | 29,354 | 25,973 | 22,664 | 18,769 |
| Retained earnings | 35,797 | 31,673 | 27,260 | 23,307 | 18,968 |